Match!
Headache
IF
3.75
Papers
7507
Papers 7604
1 page of 761 pages (7,604 results)
Newest
When treating migraine patients in the current era of Coronavirus Disease 2019 (COVID-19), many institutions have moved away from face-to-face procedures like onabotulinumtoxinA injections,(1) sometimes transitioning to the newer CGRP antibodies for migraine prevention. However, despite our best efforts to mitigate viral transmission, many of our migraine patients may eventually be exposed to SARS-CoV2. While most patients will have mild to moderate symptoms, a subset will become severely ill, w...
Source
#2Shweta Shah (Amgen)
Last. Todd J. Schwedt (Mayo Clinic)H-Index: 28
view all 9 authors...
BACKGROUND: Migraine is associated with debilitating symptoms that can affect daily functioning. "My Migraine Voice" was a large, cross-sectional, multi-country online survey aimed at understanding disease burden directly from people with migraine. OBJECTIVE: This study reports on the social and economic impacts of migraine, specifically the impact on activities of daily living and the costs of migraine, from the point of view of people with migraine in the United States. METHODS: The online sur...
Source
#1Marcello SilvestroH-Index: 4
Last. Antonio RussoH-Index: 71
view all 5 authors...
BACKGROUND: Monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) or its receptor have emerged as effective and well-tolerated preventive medications for migraine. The key role played by CGRP has been recently demonstrated also in the pathophysiology of cluster headache (CH), paving the way for studies aimed to investigate the effectiveness of mABs targeting CGRP also in CH. However, no trials have been conducted so far to test the efficacy and tolerability of erenumab as C...
Source
#1Ashhar S. Ali (WSU: Wayne State University)H-Index: 6
The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.
Source
Source
#1Dana P. Turner (Harvard University)H-Index: 12
#2Hao Deng (Harvard University)H-Index: 6
Source
#1Gretchen E. Tietjen (UT: University of Toledo)H-Index: 30
Source
#1Samantha Irwin (UCSF: University of California, San Francisco)H-Index: 2
#2Joanne Kacperski (UC: University of Cincinnati)H-Index: 6
Last. Reena Gogia Rastogi (UA: University of Arizona)H-Index: 1
view all 3 authors...
BACKGROUND: Headache attributed to mild traumatic injury of the head (aka: mild traumatic brain injury, mTBI), frequently abbreviated to Post-Traumatic Headache (PTH), is one of the most common and disabling symptoms after a head injury. PTH often phenotypes to migraine. Evidence for treating PTH in the pediatric population is limited. Widely accepted guidelines do not exist to aid the clinician and there are currently no placebo-controlled trials for the pharmacologic management of PTH in this ...
Source
#1Rebecca Erwin Wells (Wake Forest Baptist Medical Center)H-Index: 14
#2Lauren Strauss (Wake Forest Baptist Medical Center)H-Index: 3
Source
#1Marzieh Eghtesadi (UdeM: Université de Montréal)H-Index: 2
#2Guillaume Marquis-Gravel (Durham University)H-Index: 2
Source
12345678910
Top fields of study
Physical therapy
Migraine
Anesthesia
Stroke
Medicine